Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunvozertinib + Anlotinib Maintenance in Transformed SCLC
NCT06634667Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- Nov 2024
- Primary completion
- Aug 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunvozertinib and anlotinib in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), sponsored by Hunan Cancer Hospital. Primary endpoint: Progression-Free Survival up to 36 months. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
sunvozertinibanlotinib
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06634667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06634667.